Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.83 |
| ▸ | FBP1 | P09467 | 2/20 | 0.83 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.74 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.74 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.74 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.74 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.74 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.74 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.74 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.74 |
| ▸ | ILK | Q13418 | 1/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.62 |
| ▸ | INSR | P06213 | 1/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.62 |
| ▸ | FLT4 | P35916 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1507616 | 0.91 | EGFR (1.00) | EGFRFBP1ERBB2HDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL1507764 | 0.90 | EGFR (0.98) | EGFRFBP1ERBB2HDAC3HDAC4 | |
| SCHEMBL2615523 | 0.88 | EGFR (0.80) | EGFRFBP1ERBB2HDAC3HDAC4 | |
| SCHEMBL1507449 | 0.88 | EGFR (0.80) | EGFRFBP1ERBB2HDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL1507642 | 0.87 | EGFR (0.78) | EGFRFBP1ERBB2HDAC3HDAC4 | |
| SCHEMBL12426796 | 0.87 | EGFR (0.78) | EGFRFBP1ERBB2HDAC3HDAC4 | |
| SCHEMBL30207668 | 0.86 | EGFR (0.85) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL31491085 | 0.86 | EGFR (0.85) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL14964773 | 0.86 | EGFR (0.85) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL28520911 | 0.86 | EGFR (0.85) | EGFRFBP1ERBB2AURKAINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780342-B1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-06-01 | — | — | EP | disclosed |
| US-9181277-B2 | Aminoquinazoline derivatives and their salts and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-10 | — | — | US | disclosed |
| US-9181277-B2 | Aminoquinazoline derivatives and their salts and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-10 | — | — | US | disclosed |
| US-9181277-B2 | Aminoquinazoline derivatives and their salts and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-10 | — | — | US | disclosed |
| EP-2780342-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | Sunshine Lake Pharma Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-08-14 | — | — | US | disclosed |
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-08-14 | — | — | US | disclosed |
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-08-14 | — | — | US | disclosed |
| WO-2013071697-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013071697-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | ABL1, PRKDC, JAK2 | EGFR 460/4885FBP1 4095/4885ERBB2 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.